Cystatin C is a low-molecular-weight protein freely filtered by the kidneys and produced at a constant rate by all nucleated cells, making it a superior marker of glomerular filtration rate independent of muscle mass, age, and diet. It detects kidney disease earlier than creatinine alone and predicts cardiovascular mortality risk even in people with normal kidney function.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
Worried about your kidney health, or concerned that standard creatinine testing might miss early damage? Cystatin C reveals kidney function more accurately than creatinine alone, especially if you’re an athlete, elderly, have low muscle mass, or belong to any population where body composition skews creatinine readings.
Testing cystatin C matters because it catches early-stage chronic kidney disease that creatinine misses, predicts cardiovascular risk even when kidney function appears normal, and guides whether you need closer monitoring of blood pressure, glucose, or renal function as you age.
Detects early kidney disease. Cystatin C rises earlier than creatinine when glomerular filtration declines, catching CKD stage 1–2 before standard tests flag it.
Unmasked by body composition. Unlike creatinine, cystatin C is independent of muscle mass, age, and diet — making it superior in athletes, elderly, sarcopenic, amputees, and anyone with atypical body composition.
Predicts cardiovascular mortality. Elevated cystatin C forecasts cardiovascular events and all-cause mortality risk even in people with normal kidney function, reflecting subclinical vascular stress.
Guides clinical decision-making. Paired with creatinine via the average eGFR (LMREV), cystatin C refines risk stratification and justifies intensified monitoring or intervention.
Better than creatinine alone in common scenarios. Particularly useful in athletes and the elderly, where creatinine-based eGFR is systematically misleading.
Flagged by major Swedish guidelines. Standard vårdcentral protocol in Sweden now includes cystatin C alongside creatinine for robust kidney assessment.
The protein and its physiology. Cystatin C is a cysteine protease inhibitor — a small 13 kDa protein produced at a constant, stable rate by all nucleated cells in your body. Because production is virtually constant and independent of age, sex, muscle mass, diet, and inflammation, it serves as an ideal endogenous filtration marker. The glomerulus freely filters cystatin C into the urine; most is then reabsorbed and catabolized by the proximal tubule, so virtually none escapes into urine in healthy kidneys. When glomerular filtration declines, blood cystatin C rises proportionally.
Why it trumps creatinine. Creatinine is produced by muscle as a byproduct of creatine phosphate metabolism. In athletes (high muscle mass), elderly (low muscle mass), sarcopenic individuals, and amputees, creatinine-based estimates of GFR are systematically wrong — athletes appear falsely protected, elderly appear falsely impaired, and sarcopenic individuals hide true kidney disease behind deceptively low creatinine. Cystatin C, by contrast, is indifferent to these factors. It also rises earlier when kidney function begins to slip, making it the more sensitive marker for detecting early CKD.
Confounders and nuances. Thyroid status affects cystatin C: hyperthyroidism raises it, hypothyroidism lowers it. Glucocorticoids increase production slightly. Obesity can paradoxically lower cystatin C due to altered renal hemodynamics. These confounders are less dramatic than those affecting creatinine, but they matter when interpreting borderline results.
Unmasks subclinical kidney disease. Cystatin C detects glomerular filtration decline that creatinine misses, particularly in early CKD where interventions (blood pressure control, metabolic optimization) are most effective.
Predicts cardiovascular risk beyond kidney function. Elevated cystatin C forecasts major adverse cardiovascular events and mortality independently of eGFR category, signaling endothelial dysfunction and systemic vascular stress even in ’normal’ kidney function ranges.
Body-composition agnostic. In athletes, the elderly, and anyone with non-standard body composition, cystatin C provides clinically valid kidney assessment where creatinine misleads.
Guides intervention intensity. Combined cystatin C and creatinine (average eGFR per LMREV) refines risk stratification and determines whether closer monitoring, blood pressure targets, or nephroprotective strategies are justified.
Standard Swedish reference (vårdcentralen): < 1.0 mg/L (age and lab-dependent, typically 0.5–1.0 mg/L for adults).
Loovi optimal (longevity): < 0.8 mg/L, reflecting earlier detection of subclinical decline and minimized cardiovascular risk.
Aggressive (family history of CKD or established ASCVD): < 0.7 mg/L.
Cystatin C rises gradually with age and even minor elevations above 1.0 mg/L warrant investigation for kidney disease or vascular stress. The shift from < 1.0 to < 0.8 mg/L reflects the longevity principle: catching decline early is far more effective than waiting for clinical thresholds.
Low cystatin C (< 0.5 mg/L). Rare and typically benign — reflects robust glomerular filtration and low renal stress. May occur in young, very healthy individuals or occasionally in hyperthyroidism.
Optimal cystatin C (0.5–0.8 mg/L). Excellent kidney function with minimal cardiovascular risk signal. This is the longevity target. People in this range have normal GFR and low risk of progressive kidney disease.
High-normal cystatin C (0.8–1.0 mg/L). Still within standard vårdcentral reference range but signals subclinical glomerular stress. Often the first sign of declining kidney function before creatinine rises. May co-occur with hypertension, metabolic syndrome, or early diabetes. Warrants investigation of kidney disease risk factors and closer monitoring.
Elevated cystatin C (> 1.0 mg/L). Indicates reduced glomerular filtration rate and warrants evaluation for chronic kidney disease. Also predicts cardiovascular event risk independently. Investigate underlying causes: hypertension, diabetes, glomerulonephritis, medication effects (NSAIDs, ACE inhibitors at baseline), or systemic disease. Assess blood pressure, glucose, proteinuria, and consider imaging if no clear driver emerges.
Factors that influence cystatin C. Thyroid status is the most clinically relevant confounder — verify TSH if cystatin C is borderline. Glucocorticoids (including inhaled steroids) raise it mildly. Obesity can paradoxically lower it. Acute illness, intense exercise within 48 hours, and recent vaccination do not meaningfully affect cystatin C, making it more stable than creatinine day-to-day.
Declining glomerular filtration. Any process that damages the glomerulus (diabetes, hypertension, IgA nephropathy, membranous disease, lupus) reduces kidney filtration and raises cystatin C proportionally. This is the primary driver in clinical practice.
Systemic vascular disease. Atherosclerosis and endothelial dysfunction can manifest as elevated cystatin C even with preserved eGFR, particularly in people with metabolic syndrome, smoking history, or chronic inflammation (high hs-CRP).
Thyroid dysfunction. Hyperthyroidism raises cystatin C via increased protein turnover; hypothyroidism lowers it. This is the most common non-renal driver of abnormal cystatin C in population screening.
Glucocorticoid exposure. Chronic corticosteroid use (including high-dose inhaled) mildly elevates cystatin C independent of renal function changes.
Obesity and metabolic dysfunction. Metabolic syndrome, insulin resistance, and non-alcoholic fatty liver disease associate with elevated cystatin C, reflecting both glomerular hyperfiltration stress and systemic endothelial dysfunction.
Blood pressure optimization. Hypertension drives glomerular damage progressively. Tight BP control (especially in diabetics and those with proteinuria) reduces cystatin C elevation and slows CKD progression. This is the single most effective lever.
Glycemic control. Chronic hyperglycemia damages the glomerulus through multiple pathways — glucose toxicity, AGE formation, and pro-inflammatory signaling. Improving fasting glucose and HbA1c reduces glomerular stress and cystatin C burden in diabetics and pre-diabetics alike.
Metabolic health and weight management. Insulin resistance and obesity drive both glomerular hyperfiltration and systemic endothelial stress. Improving insulin sensitivity through training, nutrition, and sleep reduces metabolic load on the kidneys.
Anti-inflammatory lifestyle. Chronic systemic inflammation (tracked by hs-CRP, IL-6) accelerates glomerular and vascular damage. Sleep optimization, training consistency, and dietary anti-inflammatory patterns (Mediterranean-style) reduce inflammatory burden.
Medication considerations. ACE inhibitors and ARBs reduce glomerular hyperfiltration and protect the kidney in hypertensives and diabetics — these are standard therapy. NSAIDs and certain antibiotics can acutely worsen cystatin C; minimize use where possible. Verify thyroid medication dosing if TSH is elevated, as thyroid replacement affects cystatin C.
Optimization of cystatin C depends on the individual’s underlying driver — whether it’s blood pressure, glucose control, metabolic health, or thyroid status. This is exactly the personalization layer that a Loovi longevity consultation maps out using your full biomarker profile.
Cystatin C alone tells you glomerular function, but not the full renal story or cardiovascular context. Pairing it with creatinine (to calculate average eGFR per Swedish LMREV guidelines) catches the body-composition blind spots in both markers — if both are elevated, kidney disease is real; if only cystatin C is high, you’re looking at subclinical disease or vascular stress; if only creatinine is high, muscle mass may be the culprit, not kidney function.
Beyond kidney markers, cystatin C context demands testing urea and albumin (proteinuria markers), blood pressure, glucose and HbA1c (to identify diabetes as a driver), hs-CRP (to assess inflammatory load), and TSH (to rule out thyroid confounders). A single elevated cystatin C in a 25-year-old athlete means something entirely different than the same value in a 65-year-old with metabolic syndrome and hypertension.
This is where Loovi excels. Our membership tracks 120+ biomarkers annually — your full kidney panel, metabolic health, inflammation, thyroid status, and cardiovascular risk markers in one integrated view. Combined with unrushed 1-on-1 longevity doctor consultations, physical strength and VO2 testing, and an evolving personalized health plan, you get the precision interpretation and actionable next steps that cystatin C testing alone cannot provide.
This pattern — discordance — suggests early-stage kidney disease or subclinical glomerular stress that creatinine hasn’t caught yet. It’s often the first sign of CKD progression and warrants closer monitoring of blood pressure, glucose, and urine albumin-to-creatinine ratio. It also signals cardiovascular risk even if eGFR appears normal, so evaluate blood pressure control and metabolic health.
When both rise together, true kidney disease is present. The average eGFR (using both markers) provides a more robust estimate of GFR than either alone. Investigate underlying causes: hypertension, diabetes, proteinuria, family history of kidney disease, or medication effects. Refer to nephrology if eGFR < 30 or if there’s rapid decline.
Yes, meaningfully. Hyperthyroidism raises cystatin C, hypothyroidism lowers it. If your cystatin C is borderline-high, verify your TSH is optimal — thyroid optimization alone may normalize cystatin C without indicating true kidney disease. This is why TSH testing pairs naturally with cystatin C in preventive screening.
Not ’better’ — complementary. Cystatin C is superior in detecting early disease and in populations where creatinine is misleading (athletes, elderly, sarcopenic). Creatinine reflects muscle-derived production and can flag sarcopenia itself. Together (as average eGFR per Swedish guidelines) they give you the full picture. Testing only one is a half-measure.
Yes — cystatin C is now standard in most Swedish vårdcentral labs, especially for patients with hypertension, diabetes, or family history of kidney disease. It’s typically run alongside creatinine at no extra cost. Ask your primary care doctor to include it in routine health screening if you’re in a risk category.
Kidney function responds slowly — expect 6–12 months of consistent blood pressure and glucose control before cystatin C begins to fall meaningfully. The biology is gradual because glomerular adaptation and endothelial repair take time. Early intervention prevents further decline far more reliably than reversing established damage.
Not worry, but act. A value of 0.9 mg/L is still in the standard reference range but sits above the longevity optimal of < 0.8 mg/L. It signals subclinical glomerular stress and warrants a check of blood pressure, fasting glucose, and TSH. If all are normal, retest in 6–12 months. If any are abnormal, optimize them first.
Elevated cystatin C is a strong predictor of future GFR decline, especially if it rises over serial testing. It’s also one of the best independent predictors of cardiovascular events and mortality, even in people with normal ‘eGFR’ by standard criteria. This is why longitudinal tracking in Loovi — year-over-year comparison — is so powerful for early detection and intervention.
Unlike creatinine, cystatin C is stable around exercise. You don’t need to avoid testing the day after a hard workout. Fasting is also not required. This stability is one of cystatin C’s advantages as a marker — it doesn’t bounce around with transient factors the way creatinine does.
Very low cystatin C is rare and typically benign — just reflects young, healthy kidneys. Occasionally seen in hyperthyroidism, where elevated protein turnover lowers cystatin C without indicating disease. Check TSH to be sure. If TSH is normal and you have normal kidney function, very low cystatin C simply means robust renal reserve.
